Form 4: Calidi Biotherapeutics Director Acquires Stock Options
SEC Form 4 Filing
Scott Leftwich, a director at Calidi Biotherapeutics, acquired non-qualified stock options for 20,217 shares of common stock.
Summary
- On October 15, 2024, a Form 4 filing was submitted to the SEC regarding Scott Leftwich's transaction with Calidi Biotherapeutics, Inc.
- Scott Leftwich, a director of Calidi Biotherapeutics, acquired non-qualified stock options to purchase 20,217 shares of the company's common stock.
- The options were granted on September 20, 2024, with an exercise price of $1.09 per share, which was the closing price on the grant date.
- The options vest in monthly installments over one year, starting from the grant date.
- Andrew Jackson, Attorney-in-fact, signed the report on behalf of Scott Leftwich.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to stock option grants, indicating a neutral sentiment.
Industry Context
This filing is a routine disclosure of stock option grants to a company director, which is a common practice in publicly traded companies to incentivize and align the interests of management with shareholders.
Key Dates
| Date | Description |
|---|---|
| 09/20/2024 | Grant date of the non-qualified stock options. |
| 10/11/2024 | Date of the transaction. |
| 10/15/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.